Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?


Granulosa cell tumours of the ovary comprise approximately 3-5% of all ovarian neoplasms (Williams, 1985). They are sometimes associated with secretion of oestrogens, and less commonly androgens and progestagens. These tumours often have a protracted history and can recur many years after excision of the original tumour. Treatment of metastatic tumour generally involves radiotherapy to achieve disease control at metastatic sites (Simmons & Sciarra, 1967) or chemotherapy (Camlibel & Caputo, 1983). Extraabdominal spread is one of the factors associated with a poor prognosis (Fox et al., 1975). We document here the response of metastatic granulosa cell tumour of the ovary in two patients to therapy to oral medroxyprogesterone acetate (MPA).


0 Figures and Tables

    Download Full PDF Version (Non-Commercial Use)